ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00296218
First received: February 22, 2006
Last updated: October 14, 2009
Last verified: October 2009
  Purpose

Primary Objective

  • The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in comparison to a similar regimen of enalapril.

Secondary Objectives

  • To compare both regimens on several other biological parameters which have demonstrated their relevance and their predictive clinical value (ie BNP, microalbuminuria, troponin I …) in this patient population.
  • To compare on the above parameters the early initiation of treatment versus the initiation of treatment at hospital discharge.

Condition Intervention Phase
Myocardial Ischemia
Hypertension
Drug: Irbesartan
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation.

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • comparison of the relative change from baseline in hsCRP at day 60 between the two treatment groups

Secondary Outcome Measures:
  • Relative change from baseline of hsCRP at discharge
  • Changes from baseline in BNP and Microalbuminuria (MAU) at discharge and day 60
  • Change of Troponin I from baseline at discharge
  • In addition at baseline, discharge and D60 the following parameters will be evaluated and their evolution compared in the two treatment groups: IL6, CD 40 L, sPLA2 and Lp-PLA2, IMA, MMP-9, MPO (myeloperoxydase), aldosterone
  • Blood pressure at discharge, D15 and D60.
  • The early versus late (at hospital discharge) initiation of treatment will also be evaluated on the above-listed parameters.
  • & Safety outcomes

Estimated Enrollment: 440
Study Start Date: February 2006
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter:

Inclusion Criteria

  • Patient hospitalised with ischemic symptoms (last episode within the last 48 hours before randomization) and at least one of the following characteristics of NSTEACS (non-ST-segment-elevation acute coronary syndromes):

    • ECG ST or T changes (ST depression or transient elevation of at least 1mm or T wave changes in at least 2 leads)
    • Positive troponin (according to local threshold)

Exclusion Criteria

  • Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study WOCBP using a prohibited contraceptive method (not applicable)
  • Women who are pregnant or breast feeding
  • Women with a positive pregnancy test on enrolment or prior to study drug administration
  • Patient with dementia
  • Persistent ST segment elevation at ECG
  • Systolic blood pressure < 100 mmHg
  • Bilateral stenosis of renal artery
  • Creatinine clearance < or = 30ml/mn
  • Congestive heart failure with symptoms consistent with New York Heart Association (NYHA) class III or IV.
  • Aortic or mitral valve stenosis
  • Hypertrophic cardiomyopathy
  • Connective tissue disease with vascular involvement
  • Angioplasty, surgery or trauma within the last 3 months
  • Coronarography or angioplasty planned to be performed or performed before baseline sampling
  • Febrile (≥ 38°C) disease, known concomitant viral or bacterial infection, chronic auto immune disease, chronic inflammatory disease, known cancer in evolution
  • Hyperkalemia: serum potassium > 5.5mmol/l
  • Sensitivity or intolerance to Angiotensin receptor blockers (ARBs) : olmesartan, candesartan, irbesartan, eprosartan, losartan, telmisartan, valsartan and/or any other ARB currently or previously in development.
  • Sensitivity or intolerance to Angiotensin-converting Enzyme Inhibitors (ACE-I) : benazepril, captopril, enalapril, lisinopril, trandolapril, ramipril, quinapril, and/or any other ACE-I currently or previously in development.
  • Chronic steroid or non-steroidal anti inflammatory drugs (NSAIDs) use. Aspirin is permitted.
  • Treatment with allopurinol or procaïnamide
  • Concomitant use of potassium sparing diuretics (eg. spironolactone, triamterene or amiloride), potassium preparations or salt substitutes containing potassium
  • Treatment with Lithium
  • Immunosupressive medication
  • Administration of any other investigational drug in the last 30 days before enrolment and during the course of the study
  • Treatment with ARB or ACE inhibitor within the last 3 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00296218

Locations
United States, New Jersey
Sanofi-Aventis
Bridgewater, New Jersey, United States
Belgium
Sanofi-Aventis
Brussels, Belgium
Canada
Sanofi-Aventis
Laval, Canada
France
Sanofi-Aventis
Paris, France
Germany
Sanofi-Aventis
Berlin, Germany
Hungary
Sanofi-Aventis
Budapest, Hungary
Italy
Sanofi-Aventis
Milan, Italy
Netherlands
Sanofi-Aventis
Gouda, Netherlands
Spain
Sanofi-Aventis
Barcelona, Spain
Switzerland
Sanofi-Aventis
Meyrin, Switzerland
United Kingdom
Sanofi-Aventis
Guildford, United Kingdom
Sponsors and Collaborators
Sanofi
Bristol-Myers Squibb
Investigators
Study Director: Catherine Domenger, MD Sanofi
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00296218     History of Changes
Other Study ID Numbers: PM_C_0024, EudraCT #: 2005-002161-36
Study First Received: February 22, 2006
Last Updated: October 14, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Myocardial Ischemia
Coronary Artery Disease
Hypertension
Ischemia
Acute Coronary Syndrome
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Pathologic Processes
Angina Pectoris
Chest Pain
Pain
Signs and Symptoms
Irbesartan
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014